Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Healthy Living Europe.
Press releases published on June 12, 2025
DBV Technologies participera au prochain congrès EAACI 2025
GlobeNewswire
·
June 12, 2025
Châtillon, France, le 12 juin (22:30 CEST) 2025 DBV Technologies participera au prochain congrès EAACI 2025 DBV Technologies (Euronext : DBV – ISIN : FR0010417345 – Nasdaq Stock Market: DBVT ; CUSIP : 23306J309), une société biopharmaceutique en phase …
DBV Technologies to Participate in Upcoming EAACI Congress 2025
GlobeNewswire
·
June 12, 2025
Châtillon, France, June 12, 2025 DBV Technologies to Participate in Upcoming EAACI Congress 2025 DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT – CUSIP: 23306J309), a clinical-stage biopharmaceutical company, today …
FibroGen Announces 1-for-25 Reverse Stock Split
GlobeNewswire
·
June 12, 2025
SAN FRANCISCO, June 12, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that it will implement a 1-for-25 reverse stock split of its issued and outstanding common stock ("Reverse Stock Split"), effective at 5:00 p.m. Eastern Time on …
Galapagos to Present New ATALANTA-1 CAR-T Data at EHA 2025, Highlighting Low Toxicity and Rapid, Decentralized Delivery of Fresh, Early-Memory-Enriched GLPG5101 in R/R NHL
GlobeNewswire
·
June 12, 2025
Data reported from the ongoing ATALANTA-1 Phase 1/2 study in a heavily pretreated relapsed refractory non-Hodgkin’s Lymphoma (R/R NHL) patient population demonstrate low rates of high-grade toxicities Of the 64 patients enrolled, 61 received treatment, …
Galapagos zal nieuwe ATALANTA-1 CAR-T data presenteren op EHA 2025, met lage toxiciteit en snelle, gedecentraliseerde toediening van vers, early-memory-verrijkt GLPG5101 bij R/R NHL
GlobeNewswire
·
June 12, 2025
Gegevens uit de lopende ATALANTA-1 fase 1/2-studie bij een zwaar voorbehandelde patiëntengroep met recidief/refractair non-Hodgkinlymfoom (R/R NHL) tonen lage percentages van hooggradige toxiciteiten aan Van de 64 ingeschreven patiënten werden er 61 …
Starton Therapeutics Announces Phase 2a Clinical Trial for Continuous Low-Dose Lenalidomide (STAR-LLD) in Multiple Myeloma Open for Enrollment
GlobeNewswire
·
June 12, 2025
Gabrail Cancer …
SPECTRA EXPANDS AVAILABLE SPACE FOR FULFILLMENT CLIENTS
EIN Presswire
·
June 12, 2025
In order to meet increasing customer demand, Spectra has increased its inventory capacity for 3PL clients. COLUMBIA, SC, UNITED STATES, June 12, 2025 /EINPresswire.com/ -- Spectra specializes in end-to-end third-party logistics (3PL) services for …
Centurion Service Group to auction all assets following the closure of Rockledge Hospital in Rockledge, FL
GlobeNewswire
·
June 12, 2025
Franklin Park, Illinois, June 12, 2025 (GLOBE NEWSWIRE) -- Centurion Service Group, an industry-leading medical equipment life-cycle company, has been selected to auction all medical and non-medical assets of Rockledge Hospital in Rockledge, FL. All …
Private Donors Give $350,000 To Precision Medicine Study for Colorectal Cancer Patients
GlobeNewswire
·
June 12, 2025
Springfield, Mo., June 12, 2025 (GLOBE NEWSWIRE) -- Philanthropic support from private donors is what’s helping fund a new study focused on advancing precision medicine for metastatic colorectal cancer patients. The Ron and Martha Doornink Foundation is …
Artist Ivory Estella Balliol Honors and Advocates for Adriana Smith—Woman on Life Support—with New Artwork
EIN Presswire
·
June 12, 2025
Powerful new artwork titled "Too Much Labor" by fine artist Ivory Estella Balliol will be gifted to the family of Adriana Smith, who is still on life support. MALIBU, CA, UNITED STATES, June 11, 2025 /EINPresswire.com/ -- In a powerful intersection of …
Catheter Precision, Inc. Comments on Recent Market Activity
GlobeNewswire
·
June 12, 2025
FORT MILL, S.C., June 12, 2025 (GLOBE NEWSWIRE) -- Catheter Precision, Inc. (NYSE American: VTAK), a U.S.-based innovative medical device company focused on electrophysiology products, is issuing this press release in response to recent increases in …
Arcturis and Leeds Teaching Hospitals Enter Strategic Partnership
EIN Presswire
·
June 12, 2025
Long-term agreement to focus on generation of regulatory grade real-world datasets to advance development and adoption of new medicines OXFORD, UNITED KINGDOM, June 12, 2025 /EINPresswire.com/ -- Arcturis, the UK leader in the curation of deep, multi- …
US Lab Partners and SciSure Launch Strategic Partnership to Transform EHS Services and Lab Operations
EIN Presswire
·
June 12, 2025
SciSure and US Lab Partners launch a Virtual Incubator Model to bring top-tier lab software and EHS support to emerging life science labs. BOSTON, MA, UNITED STATES, June 12, 2025 /EINPresswire.com/ -- SciSure, the Scientific Management Platform (SMP) …
Global Uterine Fibroids Treatment Devices Market is Expected to Showcase a Significant Growth at a CAGR of ~9% by 2032 | DelveInsight
GlobeNewswire
·
June 12, 2025
New York, USA, June 12, 2025 (GLOBE NEWSWIRE) -- Global Uterine Fibroids Treatment Devices Market is Expected to Showcase a Significant Growth at a CAGR of ~9% by 2032 | DelveInsight The growing prevalence of uterine fibroids, especially among women of …
Giant-Cell Arteritis Market Heats up with AbbVie’s RINVOQ Approval | DelveInsight
GlobeNewswire
·
June 12, 2025
New York, USA, June 12, 2025 (GLOBE NEWSWIRE) -- Giant-cell Arteritis Market Heats up with AbbVie’s RINVOQ Approval | DelveInsight The FDA has approved AbbVie’s RINVOQ (upadacitinib) for the treatment of giant cell arteritis, making it the ninth approved …
First of Its Kind in the Region: KFSHRC Successfully Performs Endoscopic Sleeve Gastroplasty on Kidney Transplant Patient
GlobeNewswire
·
June 12, 2025
RIYADH, Saudi Arabia, June 12, 2025 (GLOBE NEWSWIRE) -- In a medical achievement considered the first of its kind in the region, King Faisal Specialist Hospital …
Syndax Announces Publication of Revumenib Data from the BEAT AML Trial in the Journal of Clinical Oncology and Simultaneous Presentation at EHA 2025
GlobeNewswire
·
June 12, 2025
– Revumenib was generally well-tolerated in combination with venetoclax/azacitidine in older, newly diagnosed mNPM1 and KMT2Ar AML patients – – Promising clinical activity and deep responses observed with 67% (29/43) CR rate, 88% (38/43) ORR, and 100% (37/ …
Shuttle Pharma Announces Reverse Stock Split will Become Effective on June 16, 2025, at 12:01 a.m., Eastern Time
GlobeNewswire
·
June 12, 2025
GAITHERSBURG, Md., June 12, 2025 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma” or the “Company”), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer …
Aptose Presents Safety, Response, and MRD Clinical Data from TUSCANY Phase 1/2 Clinical Trial of Tuspetinib Triplet Therapy in Newly Diagnosed AML at the 2025 EHA Congress
GlobeNewswire
·
June 12, 2025
Addition of TUS to standard of care VEN+AZA creates a well-tolerated and mutation agnostic frontline triple drug therapy for newly diagnosed AML AML patients with diverse mutations, including TP53-mutated/CK and FLT3-wildtype, safely achieved complete …
Apex Labs Granted Israel MoH Approval to Expand Phase 2b Macrodose Psilocybin PTSD Clinical Trial
GlobeNewswire
·
June 12, 2025
Israel’s Ministry of Health (MoH) approval to add additional sites to APEX SUMMIT-90 160 patient phase 2b macrodose clinical trial: Tel Aviv University (TAU)’s Institute for Psychedelic Research located at the Sagol Brain Institute (SGI) in Tel-Aviv …